INT239412

From wiki-pain
Revision as of 17:35, 21 September 2012 by Daniel (Talk | contribs)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Context Info
Confidence 0.28
First Reported 2008
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 8
Total Number 8
Disease Relevance 5.39
Pain Relevance 0.18

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (ABL1) protein modification process (ABL1) mitochondrion (ABL1)
nucleolus (ABL1) nucleus (ABL1) DNA binding (ABL1)
Anatomy Link Frequency
plasma 1
ABL1 (Homo sapiens)
Pain Link Frequency Relevance Heat
adenocard 1 99.72 Very High Very High Very High
Potency 4 88.60 High High
rheumatoid arthritis 1 87.92 High High
Pain 16 37.48 Quite Low
cytokine 20 5.00 Very Low Very Low Very Low
headache 17 5.00 Very Low Very Low Very Low
pruritus 8 5.00 Very Low Very Low Very Low
corticosteroid 3 5.00 Very Low Very Low Very Low
Spinal cord 3 5.00 Very Low Very Low Very Low
Paresthesia 3 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Disease 108 98.56 Very High Very High Very High
Congenital Anomalies 35 98.24 Very High Very High Very High
Hypolipidemia 33 97.62 Very High Very High Very High
Ophthalmoplegia 3 96.40 Very High Very High Very High
Myeloid Leukemia 122 95.48 Very High Very High Very High
Anisocoria 3 95.04 Very High Very High Very High
Ocular Toxicity (including Many Sub-types) 30 94.08 High High
Strabismus 3 93.20 High High
Gastrointestinal Stromal Tumor 104 92.32 High High
Neuropathic Pain 18 92.12 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Although there are multiple mechanisms involved in the emergence of resistance, usually resistance develops because of a mutation in the adenosine triphosphate-binding pocket of the BCR-ABL1 oncoprotein, which makes imatinib binding impossible.
BCR-ABL1 oncoprotein Binding (binding) of associated with adenocard
1) Confidence 0.28 Published 2010 Journal BMC Blood Disord Section Body Doc Link PMC3017013 Disease Relevance 0.22 Pain Relevance 0.05
At age 11, routine blood tests revealed acanthocytosis with undetectable plasma cholesterol and triglyceride, which together with normal parental lipid profiles suggested a diagnosis of ABL.
ABL Binding (diagnosis) of in plasma associated with hypolipidemia
2) Confidence 0.26 Published 2008 Journal Orphanet J Rare Dis Section Body Doc Link PMC2467409 Disease Relevance 0.54 Pain Relevance 0
Furthermore, anecdotal evidence, such as the history of the two patients reported here, suggests that vitamin replacement treatment can reduce morbidity and delay early mortality associated with ABL.
ABL Binding (associated) of
3) Confidence 0.25 Published 2008 Journal Orphanet J Rare Dis Section Body Doc Link PMC2467409 Disease Relevance 0.41 Pain Relevance 0
Of note, all ABL patients who received vitamin therapy prior to 2 years of age were free of the neurologic and systemic complications that are usually associated with untreated ABL [17].
ABL Binding (associated) of
4) Confidence 0.25 Published 2008 Journal Orphanet J Rare Dis Section Body Doc Link PMC2467409 Disease Relevance 1.40 Pain Relevance 0
The first of these disease-tailored products has been imatinib mesylate (IM) which blocks the ATP-binding pocket on the BCR-ABL tyrosine-kinase and thus prevents the activation of this enzyme which plays the key role in the pathogenesis of CML [13].
BCR-ABL Binding (binding) of associated with myeloid leukemia and disease
5) Confidence 0.15 Published 2010 Journal Clinical and Developmental Immunology Section Body Doc Link PMC3004381 Disease Relevance 1.18 Pain Relevance 0.04
Bosutinib binds to an intermediate form of BCR-ABL [8].
BCR-ABL Binding (binds) of
6) Confidence 0.07 Published 2010 Journal J Hematol Oncol Section Body Doc Link PMC3000369 Disease Relevance 0.38 Pain Relevance 0.04
Dasatinib has a completely different chemical structure to imatinib and, unlike imatinib and nilotinib, binds BCR-ABL in the active conformation [10,11].
BCR-ABL Binding (binds) of
7) Confidence 0.07 Published 2010 Journal J Hematol Oncol Section Body Doc Link PMC3000369 Disease Relevance 0.36 Pain Relevance 0.04
Imatinib is a selective tyrosine kinase inhibitor which binds KIT, Bcr-Abl, PDGFA/PDGFB.
Bcr-Abl Binding (binds) of
8) Confidence 0.04 Published 2010 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2819895 Disease Relevance 0.91 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox